Oxcia AB presents positive effects of OXC-201 in lung tissue from patient with Idiopatic Pulmonary Fibrosis

Oxcia presents new preclinical data on OXC-201 at the 7th IPF summit in Boston, September 19-21 and European Respiratory Society (ERS) International Congress 2023 September 9–13.  Lung tissue from IPF patients express high levels of several fibrotic biomarkers. Treatment with clinically relevant doses of OXC-201 demonstrated robust dose-dependent reduction of a number of the most important fibrosis-related biomarkers such as TGF-ß and collagen. These data correlate well with results from previous preclinical models, supporting OXC-201 as a potential treatment for IPF.  

Christina Kalderén, Preclinical Director, Oxcia AB comments:”We are happy to present new ex vivo data on OXC-201, our lead candidate for treatment of IPF. The new promising data strengthen our position as we take the next step towards clinical evaluation.”


Precision Cut Lung Slices (PCLuS)

PCLuS is based on lung tissue from transplanted IPF patients. Parts of the lung are tissue cultured and used to study pharmacological effects on fibrotic biomarkers. The technology is developed at FibroFind and Newcastle University.


Briefly about OXC-201

OXC-201 is a small molecule inhibitor of OGG1, a novel approach for the treatment of IPF (idiopathic pulmonary fibrosis), other fibrotic conditions and inflammatory diseases. By targeting the DNA repair enzyme OGG1 (8-oxo guanine DNA glycosylase-1), OXC-201 inhibits binding of OGG1 to DNA and thereby the modulation of gene transcription. OGG1 plays a significant role in modulating inflammation and fibrogenesis; genetic downregulation or chemical inhibition of OGG1 has been shown to protect against inflammation and fibrosis in several experimental disease models. OXC-201 is patent protected and Oxcia AB has exclusive rights under the patent to develop and commercialize OXC-201.

 EIC (European Innovation Council) has awarded Oxcia AB a grant of 2.5 million Euros within the EIC-Transition program which finances the next phase of the development of OXC-201.



For further information please contact:


Christina Kalderén, Pre-clinical Director

Email: christina.kalderen@oxcia.com


Ulrika Warpman Berglund, CEO

Email: ulrika.warpmanberglund@oxcia.com


Briefly about Oxcia

Oxcia AB conducts innovative research through its unique way of utilizing oxidative DNA damage and DNA Damage response(1) and develops novel, safe and effective treatments for patients suffering from cancer, inflammation or fibrosis. Oxcia currently has two drug candidates, both with first-in-class potential. OXC-101 is in early clinical development for the treatment of solid and hematological cancers. OXC-201 is being developed as a treatment for inflammation and fibrosis-related diseases, such as pulmonary fibrosis and allergic asthma, and is in the preclinical phase.

More information about Oxcia is available at www.oxcia.com

(Note (1): DNA Damage Response, DDR – the body's processes to in various ways repair the damage that occurs to DNA)